Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Insight Molecular Diagnostics (IMDX) EBT: 2015-2024

Historic EBT for Insight Molecular Diagnostics (IMDX) over the last 10 years, with Dec 2024 value amounting to -$61.0 million.

  • Insight Molecular Diagnostics' EBT rose 18.25% to -$11.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$61.3 million, marking a year-over-year decrease of 41.10%. This contributed to the annual value of -$61.0 million for FY2024, which is 142.84% down from last year.
  • Per Insight Molecular Diagnostics' latest filing, its EBT stood at -$61.0 million for FY2024, which was down 142.84% from -$25.1 million recorded in FY2023.
  • Insight Molecular Diagnostics' 5-year EBT high stood at -$18.6 million for FY2022, and its period low was -$61.0 million during FY2024.
  • For the 3-year period, Insight Molecular Diagnostics' EBT averaged around -$34.9 million, with its median value being -$25.1 million (2023).
  • As far as peak fluctuations go, Insight Molecular Diagnostics' EBT skyrocketed by 64.80% in 2022, and later plummeted by 142.84% in 2024.
  • Yearly analysis of 5 years shows Insight Molecular Diagnostics' EBT stood at -$31.2 million in 2020, then crashed by 69.53% to -$52.9 million in 2021, then skyrocketed by 64.80% to -$18.6 million in 2022, then tumbled by 35.05% to -$25.1 million in 2023, then slumped by 142.84% to -$61.0 million in 2024.